Claudin 18.2, is a 'Dark Horse' in Anti-tumour Therapy?In May, 2020, the world's first CAR-T therapy targeting Claudin 18.2 was approved in the US; in June, 2020, the world's first Claudin 18.2/PD-L1 bispecific antibody preclinical data was presented at the AACR; and on July...
Detailed information

GPC3: The Next-Promising Target in Cancer ImmunotherapyIn recent years, glypican-3 (GPC3) has emerged as a highly promising specific target for hepatocellular carcinoma (HCC) and other solid tumors, with its translational research advancing at an unprecedented pace. From 202...
Detailed information

Neuronal Markers and Neurodegenerative DiseasesNeurons are highly specialized nerve cells that receive and transmit electrical or chemical signals to coordinate all of the necessary functions for life. Neurons are typically composed of a cell body, dendrites, an ax...
Detailed information

Oncogenes and CancerIn fact, everyone has genes that possess the ability to cause cancer. These genes are known as proto-oncogenes, which are expressed to control normal cell processes such as proliferation, differentiation, and apoptosis. ...
Detailed information

Protein Acetylation: An Important Post-translational Modification in Eukaryotic CellsAs is well-known, post-translational modifications (PTMs) are essential mechanisms for eukaryotic cells to diversify protein functions and dynamically coordinate signaling networks. Vincent Allfrey and colleagues first...
Detailed information

Cell Cycle Markers in Focus: From Basic Research to Biomarker Discovery in OncologyFor a researcher or clinician facing a tumor sample, a critical question looms: how fast is this cancer actually growing? Accurately measuring cancer growth rate is more than an academic exercise; it shapes diagnosis, pr...
Detailed information

The Oncogene HER2: a New Target for Drug-Resistant TumorsOn March 17, 2021, a research paper entitled "Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors" [1] has attracted attention. Researchers found that the combination of MCL-1 inh...
Detailed information

NRG1: an Intriguing Therapeutic Target in DiseasesIn May 2026, the FDA approved Partner Therapeutics’ Bizengri (zenocutuzumab) for an expanded indication for the treatment of advanced cholangiocarcinoma patients with NRG1 gene fusions, making it the world’s first ta...
Detailed information

TNFR1: Elucidating Dual Mechanisms and Evolving as a Precision Therapeutic TargetTumor Necrosis Factor Receptor 1 (TNFR1) is a key molecule mediating apoptosis, necrosis, and inflammatory responses. It plays a complex role in pathological processes such as cancer, autoimmune diseases, and infections....
Detailed information

Neutralizing Antibody Stands Out Among Antiviral TherapiesHuman has been constantly struggling with various diseases from the birth. Human history documented several brutal, disastrous, and deadly diseases, such as smallpox, bubonic plague, cholera, and influenza. They broke ou...
Detailed information